title: Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy.
abstract: BACKGROUND
  Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis.
  
  
  METHODS
  We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid.
  
  
  RESULTS
  Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid-base parameters were detected between the groups.
  
  
  CONCLUSIONS
  In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed.
authors.affiliation: Department of Microbiology, Immunology and Glycobiology , Institute of Laboratory Medicine , Lund , Sweden.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Godaly
authors.affiliation: Therapeutic Fluid Research, Gambro Lundia AB, Lund, Sweden; Department of Nephrology, Lund University, Lund, Sweden.
authors.forename: Ola
authors.initials: O
authors.lastname: Carlsson
authors.affiliation: Department of Perioperative and Intensive Care , Skåne University Hospital , Lund , Sweden.
authors.forename: Marcus
authors.initials: M
authors.lastname: Broman
keywords: CRRT; critically ill patients; hypophosphataemia; intensive care medicine